You are here

All Licensing Opportunities

We are seeking a partner experienced in the field of cell therapy development and in the Chinese regulatory environment to take this technology through to first in man trials in China. The technology demonstrates in vivo efficacy with no observed toxicities. Cancer Research UK is prosecuting a patent for the technology and the relevant sequences.

CRUK is seeking an industry partner for co-development and/or exclusive licensing of its CLEC14A IP, materials and know-how, to progress anti-CLEC14A antibodies into first-in-human clinical studies.

The integrin ɑvß6 is an exciting emerging target for both imaging and therapy across many common tumour types including pancreatic, breast, oesophagus, head and neck, skin, lung and ovarian. Patent family WO2007/039728 protecting the peptide consensus sequence is available for exclusive licensing or collaborative development.

We are seeking a commercial partner interested in pursuing a co-development or direct licensing arrangement.

The integrin avß6 is an exciting emerging target for both imaging and therapy across many common tumour types including pancreatic, breast, oesophagus, head and neck, skin, lung and ovarian. Patent family WO2007/039728 protecting the peptide consensus sequence is available for exclusive licensing or collaborative development.

The Tyrer-Cuzick model has been shown in independent studies to be the most consistently accurate when compared with other available breast cancer risk assessment tools. It incorporates family history, endogenous hormonal factors, benign disease, risk factors such as age and body mass index, as well as genetic factors (including BRCA) into a single statistical model. The model has been incorporated into a computer programme, the IBIS software that gives a personalised risk estimate. IBIS is available for non-exclusive licensing for stand-alone use or for incorporation into broader software platforms.

Pages